Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5604_Библиотеки_им_академика_М_И_Перельмана.pdf
Chitosan/Carbon Nanocomposites in Drug Delivery and Cardiovascular … 435
15. Garriga R, Herrero-Continente T, Palos M, Cebolla VL, Osada J, Muñoz E, Rodríguez-Yoldi
MJ (2020) Toxicity of carbon nanomaterials and their potential application as drug delivery
systems: in vitro studies in Caco-2 and MCF-7 cell lines. Nanomater 10(8):1617
16. Li J, Li M, Tian L, Qiu Y, Yu Q, Wang X, Guo R, He Q (2020) Facile strategy by hyaluronic
acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and
enhanced breast cancer therapy. Int J Pharm 578:119122
17. Li L, YangWW, Xu DG (2019) Stimuli-responsive nanoscale drug delivery systems for cancer
therapy. J Drug Target 27(4):423–433
18. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H, Tahriri
M, Tayebi L, Hamblin MR (2019) Stimulus-responsive polymeric nanogels as smart drug
delivery systems. Acta Biomater 92:1–18
19. WHO. Cardiovascular diseases (CVDs). 2021 [cited 2022 26/10]; Available from:https://
www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
20. Francula-Zaninovic S, Nola IA (2018) Management of measurable variable cardiovascular
disease’ risk factors. Curr Cardiol Rev 14(3):153–163
21. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS (2012) Cardiovascular disease
in the developing world: prevalences, patterns, and the potential of early disease detection. J
Am Coll Cardiol 60(14):1207–1216
22. Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl
AB, Gaziano T, Hamandi A, Mowafi M, O’Farrell D, Ozaltin E, Pandya A, Prettner K,
Rosenberg L, Seligman B, Stein AZ, Weinstein C, Weiss J (2012) The global economic
burden of noncommunicable diseases (No. 8712). Program on the Global Demography of
Aging
23. Costantino S, Paneni F, Cosentino F (2016) Ageing, metabolism and cardiovascular disease.
J Physiol 594(8):2061–2073
24. Kjeldsen SE (2018) Hypertension and cardiovascular risk: general aspects. Pharmacol Res
129:95–99
25. Hobbs FR (2015) Prevention of cardiovascular diseases. BMC Med 13:1–3
26. Sánchez-Arias AG, Bobadilla-Serrano ME, Dimas-Altamirano B, Gómez-Ortega M,
González-González G (2016) Enfermedad cardiovascular: primera causa de morbilidad en
un hospital de tercer nivel. Rev Mex Cardiol 27(S3):98–102
27. Gander J, Sui X, Hazlett LJ, Cai B, Hébert JR, Blair SN (2014) Peer reviewed: factors related
to coronary heart disease risk among men: validation of the Framingham Risk Score. Prev
Chronic Dis 11
28. Ginghina C, Ungureanu C, Vladaia A, Popescu BA, Jurcut R (2009) The electrocardiographic
profile of patients with angina pectoris. J Med Life 2(1):80
29. Rea P (2015) Essential clinical anatomy of the nervous system. Academic Press
30. Khare S (2016) Risk factors of transient ischemic attack: an overview. J Mid-Life Health
7(1):2
31. Khadilkar SV (2012) Neurology: the scenario in India. J Assoc Physicians India 60:42–44
32. Grasso G, Alafaci C, Macdonald RL (2017) Management of aneurysmal subarachnoid
hemorrhage: state of the art and future perspectives. Surg Neurol Int 8
33. Miller BA, Turan N, Chau, M Pradilla G (2014) Inflammation, vasospasm, and brain injury
after subarachnoid hemorrhage. BioMed Res Int
34. Alotaibi NM, Wang JZ, Pasarikovski CR, Guha D, Al-Mufti F, Mamdani M, Saposnik
G, Schweizer TA, Macdonald RL (2017) Management of raised intracranial pressure in
aneurysmal subarachnoid hemorrhage: time for a consensus? Neurosurg Focus 43(5):E13
35. O’Brien JT, Thomas A (2015) Vascular dementia. The Lancet 386(10004):1698–1706
36. Lavorini F, Di Bello V, De Rimini ML, Lucignani G, Marconi L, Palareti G, Pesavento R,
Prisco D, Santini M, Sverzellati N, Palla A, Pistolesi M (2013) Diagnosis and treatment of
pulmonary embolism: a multidisciplinary approach. Multidiscip. Respir. Med. 8(1):1–8
37. Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. Circ Res
116(9):1509–1526
436 A. M. Mahmoud et al.
38. Huffman MD, Bhatnagar D (2012) Novel treatments for cardiovascular disease prevention.
Cardiovasc Ther 30(5):257–263
39. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ (2014) Cardioprotection and pharmacological therapies in acute myocardial infarction: challenges in the current era. World J
Cardiol 6(3):100
40. Elgendy IY, Mahtta D, Pepine CJ (2019) Medical therapy for heart failure caused by ischemic
heart disease. Circ Res 124(11):1520–1535
41. Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med
372(9):793–795
42. Iravani S, Varma RS (2022) Advanced drug delivery micro-and nanosystems for cardiovascular diseases. Molecules 27(18):5843
43. Kurakula M, Gorityala S, Patel DB, Basim P, Patel B, Kumar Jha S (2021) Trends of chitosan
based delivery systems in neuroregeneration and functional recovery in spinal cord injuries.
Polysaccharides 2(2):519–537
44. Suh JKF, Matthew HW (2000) Application of chitosan-based polysaccharide biomaterials in
cartilage tissue engineering: a review. Biomater 21(24):2589–2598
45. Bernkop-Schnürch A, Dünnhaupt S (2012) Chitosan-based drug delivery systems. Eur J Pharm
Biopharm 81(3):463–469
46. Kweon DK, Song SB, Park YY (2003) Preparation of water-soluble chitosan/heparin complex
and its application as wound healing accelerator. Biomater 24(9):1595–1601
47. Garaiova Z, Strand SP, Reitan NK, Lélu S, Størset SØ, Berg K, Malmo J, Folasire O, Bjøkøy A,
Davies CDL (2012) Cellular uptake of DNA–chitosan nanoparticles: the role of clathrin-and
caveolae-mediated pathways. Int J Biol Macromol 51(5):1043–1051
48. Ma L, Shen CA, Gao L, Li DW, Shang YR, Yin K, Zhao DX, Cheng WF,Quan DQ (2016) Antiinflammatory activity of chitosan nanoparticles carrying NF-κB/p65 antisense oligonucleotide
in RAW264.7 macropghage stimulated by lipopolysaccharide. Colloids Surf. B: Biointerfaces
142:297–306
49. Song H, Yu M, Lu Y, Gu Z, Yang Y, Zhang, M, Fu, Z, Yu C (2017) Plasmid DNA delivery:
nanotopography matters. J Am Chem Soc 139(50):18247–18254
50. Silva JM, García JR, Reis RL, García AJ, Mano JF (2017) Tuning cell adhesive properties
via layer-by-layer assembly of chitosan and alginate. Acta Biomater 51:279–293
51. Lončarević A, Ivanković M, Rogina A (2017) Lysozyme-induced degradation of chitosan:
the characterisation of degraded chitosan scaffolds. J Tissue Repair Regen 1(1):12
52. Croisier F, Jérôme C (2013) Chitosan-based biomaterials for tissue engineering. Eur Polym J
49(4):780–792
53. Deepthi S, Venkatesan J, Kim SK, Bumgardner JD, Jayakumar R (2016) An overview of
chitin or chitosan/nano ceramic composite scaffolds for bone tissue engineering. Int J Biol
Macromol 93:1338–1353
54. Okamoto Y, Watanabe M, Miyatake K, Morimoto M, Shigemasa Y, Minami S (2002) Effects
of chitin/chitosan and their oligomers/monomers on migrations of fibroblasts and vascular
endothelium. Biomater 23(9):1975–1979
55. Nagy A, Harrison A, Sabbani S, Munson RS Jr, Dutta PK, Waldman WJ (2011) Silver nanoparticles embedded in zeolite membranes: release of silver ions and mechanism of antibacterial
action. Inter. J Nanomed 6:1833–1852
56. Hasan A, Waibhaw G, Tiwari S, Dharmalingam K, Shukla I, Pandey LM (2017) Fabrication and characterization of chitosan, polyvinylpyrrolidone, and cellulose nanowhiskers
nanocomposite films for wound healing drug delivery application. J Biomed Mater Res A
105(9):2391–2404
57. Si R, Gao C, Guo R, Lin C, Li J, Guo W (2020) Human mesenchymal stem cells
encapsulated-coacervated photoluminescent nanodots layered bioactive chitosan/collagen
hydrogel matrices to indorse cardiac healing after acute myocardial infarction. J Photochem
Photobiol B: Biol 206:111789
58. Qiu T, Jiang W, Yan P, Jiao L, Wang X (2020) Development of 3D-printed sulfated chitosan
modified bioresorbable stents for coronary artery disease. Front Bioeng Biotechnol 8:462
Chitosan/Carbon Nanocomposites in Drug Delivery and Cardiovascular … 437
59. Saeednia L, Yao L, Cluff K, Asmatulu R (2019) Sustained releasing of methotrexate
from injectable and t hermosensitive chitosan–carbon nanotube hybrid hydrogels effectively
controls tumor cell growth. ACS Omega 4(2):4040–4048
60. Sharmeen S, Rahman AM, Lubna MM, Salem KS, Islam R, Khan MA (2018) Polyethylene glycol functionalized carbon nanotubes/gelatin-chitosan nanocomposite: an approach
for significant drug release. Bioact Mater 3(3):236–244
61. Wu Z, Feng W, Feng Y, Liu Q, Xu X, Sekino T, Fujii A, Ozaki M (2007) Preparation and
characterization of chitosan-grafted multiwalled carbon nanotubes and their electrochemical
properties. Carbon 45(6):1212–1218
62. Aryaei A, Jayatissa AH, Jayasuriya AC (2014) Mechanical and biological properties of
chitosan/carbon nanotube nanocomposite films. J Biomed Mater Res A 102(8):2704–2712
63. Justin R, Chen B (2014) Characterisation and drug release performance of biodegradable
chitosan–graphene oxide nanocomposites. Carbohydr Polym 103:70–80
64. Jiang L, Chen D, Wang Z, Zhang Z, Xia Y, Xue H, Liu Y (2019) Preparation of an electrically
conductive graphene oxide/chitosan scaffold for cardiac tissue engineering. Appl Biochem
Biotechnol 188:952–964
65. Kandra R, Bajpai S (2020) Synthesis, mechanical properties of fluorescent carbon dots loaded
nanocomposites chitosan film for wound healing and drug delivery. Arab J Chem 13(4):4882–
4894
66. Javanbakht S, Shaabani A (2019) Encapsulation of graphene quantum dot-crosslinked
chitosan by carboxymethylcellulose hydrogel beads as a pH-responsive bio-nanocomposite
for the oral delivery agent. Int J Biol Macromol 123:389–397
67. Abazar F, Noorbakhsh A (2020) Chitosan-carbon quantum dots as a new platform for highly
sensitive insulin impedimetric aptasensor. Sens. Actuators B: Chem. 304:127281
68. Karousis N, Suarez-Martinez I, Ewels CP, Tagmatarchis N (2016) Structure, properties,
functionalization, and applications of carbon nanohorns. Chem Rev 116(8):4850–4883
69. Li J, He Z, Guo C, Wang L, Xu S (2014) Synthesis of carbon nanohorns/chitosan/quantum
dots nanocomposite and its applications in cells labeling and in vivo imaging. J Luminesc
145:74–80
70. Rizwan M, Elma S, Lim SA, Ahmed MU (2018) AuNPs/CNOs/SWCNTs/chitosannanocomposite modified electrochemical sensor for the label-free detection of carcinoembryonic antigen. Biosens Bioelectron 107:211–217
71. Sok V, Fragoso A (2019) Amperometric biosensor for glyphosate based on the inhibition
of tyrosinase conjugated to carbon nano-onions in a chitosan matrix on a screen-printed
electrode. Microchim Acta 186:1–8
72. Ahlawat J, Asil SM, Barroso GG, Nurunnabi M, Narayan M (2021) Application of carbon nano
onions in the biomedical field: recent advances and challenges. Biomater Sci 9(3):626–644
73. Ali MS, Metwally AA, Fahmy RH, Osman R (2020) Chitosan-coated nanodiamonds: mucoadhesive platform for intravesical delivery of doxorubicin. Carbohydr Polym 245:116528
74. Chernysheva MG, Chaschin IS, Sinolits AV, Vasil’ev VG, Popov AG, Badun GA, Bakuleva
NP (2020) Chitosan-nanodiamond composites for improving heart valve biological prostheses materials: preparation and mechanical trial. Fuller Nanotub Carbon Nanostructures
28(4):256–261
75. Geldenhuys WJ, Lin L, Darvesh AS, Sadana P (2017) Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discov Today 22(2):352–365
76. Mohammed MA, Syeda JT, Wasan KM, Wasan EK (2017) An overview of chitosan
nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 9(4):53
77. Bansal V, Sharma PK, Sharma N, Pal OP, Malviya R (2011) Applications of chitosan and
chitosan derivatives in drug delivery. Adv Biol Res 5(1):28–37
78. Black DM, Bakker-Arkema RG, Nawrocki JW (1998) An overview of the clinical safety
profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Inter Med
158(6):577–584
79. Jb VK, Ramakrishna S, Madhusudhan B (2017) Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. IET
Nanobiotechnol 11(1):96–103
438 A. M. Mahmoud et al.
80. Ochiuz L, Popa G, Stoleriu I, Tomoiag˘a AM, Popa M (2013) Microencapsulation of metoprolol tartrate into chitosan for improved oral administration and patient compliance. Ind Eng
Chem Res 52(49):17432–17441
81. McGill JB (2010) Optimal use of β-blockers in high-risk hypertension: a guide to dosing
equivalence. Vasc. Health Risk Manag 6:363
82. Dadou SM, El-Barghouthi MI, Antonijevic MD, Chowdhry BZ, Badwan AA (2019) Elucidation of the controlled-release behavior of metoprolol succinate from directly compressed
xanthan gum/chitosan polymers: computational and experimental studies. ACS Biomater Sci
Eng 6(1):21–37
83. Pharmacists ASOH-S (2019) Valsartan Monograph for Professionals. Drugs. com.. Retrieved,
3. https://www.drugs.com/monograph/valsartan.html
84. Sohail M, Ahmad M, Minhas MU, Ali L, Khalid I, Rashid H (2015) Controlled delivery of
valsartan by cross-linked polymeric matrices: synthesis, in vitro and in vivo evaluation. Int J
Pharm 487(1–2):110–119
85. Bruckert E, Giral P, Tellier P (2003) Perspectives in cholesterol-lowering therapy: the role of
ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circ 107(25):3124–
3128
86. Shukr MH, Ismail S, Ahmed SM (2019) Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity. J Drug Deliv Sci Technol 49:383–395
87. Mosa IF, Abd HH, Abuzreda A, Yousif AB, Assaf N (2021) Chitosan and curcumin nanoformulations against potential cardiac risks associated with hydroxyapatite nanoparticles in
Wistar male rats. Int J Biomater
88. Wang C, Zhang Z, Chen B, Gu L, Li Y, Yu S (2018) Design and evaluation of galactosylated
chitosan/graphene oxide nanoparticles as a drug delivery system. J Colloid Interface Sci
516:332–341
89. Zavareh HS, Pourmadadi M, Moradi A, Yazdian F, Omidi M (2020) Chitosan/carbon quantum
dot/aptamer complex as a potential anticancer drug delivery system towards the release of
5-fluorouracil. Int J Biol Macromol 165:1422–1430
90. Lin C, Sun K, Zhang C, Tan T, Xu M, Liu Y, Xu C, Wang Y, Li L, Whittaker A (2020) Carbon
dots embedded metal organic framework@ chitosan core-shell nanoparticles for vitro dual
mode imaging and pH-responsive drug delivery. Microporous Mesoporous Mater 293:109775
91. Sukhodub LB, Sukhodub LF, Kumeda MO, Prylutska SV, Deineka V, Prylutskyy YI, Ritter
U (2019) C60 fullerene loaded hydroxyapatite-chitosan beads as a promising system for
prolonged drug release. Carbohydr Polym 223:115067
92. Chen D, Wang C, Jiang F, Liu Z, Shu C, Wan LJ (2014) In vitro and in vivo photothermally
enhanced chemotherapy by single-walled carbon nanohorns as a drug delivery system. J Mater
Chem B 2(29):4726–4732
93. Liu D, Su Y, Chen J, Pan H, Pan W (2023) Folic acid-chitosan oligosaccharide conjugates
decorated nanodiamond as potential carriers for the oral delivery of doxorubicin. AAPS
PharmSciTech 24(4):86
94. Anirudhan TS, Sekhar VC, Athira VS (2020) Graphene oxide based functionalized chitosan
polyelectrolyte nanocomposite for targeted and pH responsive drug delivery. Int J Biol
Macromol 150:468–479
95. Wang R, Shou D, Lv O, Kong Y, Deng L, Shen J (2017) PH-Controlled drug delivery with
hybrid aerogel of chitosan, carboxymethyl cellulose and graphene oxide as the carrier. Int J
Biol Macromol 103:248–253
96. Jafari Z, Rad AS, Baharfar R, Asghari S, Esfahani MR (2020) Synthesis and application
of chitosan/tripolyphosphate/graphene oxide hydrogel as a new drug delivery system for
Sumatriptan Succinate. J Mol Liq 315:113835
97. Guo Y, Chen Y, Han P, Liu Y, Li W, Zhu F, Fu K, Chu M (2020) Biocompatible chitosancarbon nanocage hybrids for sustained drug release and highly efficient l aser and microwave
co-irradiation induced cancer therapy. Acta Biomater 103:237–246
98. Garg T, Singh O, Arora S, Murthy RSR (2012) Scaffold: a novel carrier for cell and drug
delivery. Crit Rev Ther Drug Carrier Syst 29(1):1–63
Chitosan/Carbon Nanocomposites in Drug Delivery and Cardiovascular … 439
99. Rossi G, Broguiere N, Miyamoto M, Boni A, Guiet R, Girgin M, Kelly RG, Kwon C, Lutolf
MP (2021) Capturing cardiogenesis in gastruloids. Cell Stem Cell 28(2):230–240
100. Trombino S, Curcio F, Cassano R, Curcio M, Cirillo G, Iemma F (2021) Polymeric
biomaterials for the treatment of cardiac post-infarction injuries. Pharmaceutics 13(7):1038
101. Romagnoli C, D’Asta F, Brandi ML (2013) Drug delivery using composite scaffolds in the
context of bone tissue engineering. Clin Cases Miner Bone Metab 10(3):155
102. Fenton OS, Olafson KN, Pillai KPS, Mitchell MJ, Langer R (2018) Advances in biomaterials
for drug delivery. Adv Mater 30(29):1705328
103. Aiba SI, Minoura N, Taguchi K, Fujiwara Y (1987) Covalent immobilization of chitosan
derivatives onto polymeric film surfaces with the use of a photosensitive hetero-bifunctional
crosslinking reagent. Biomater 8(6):481–488
104. Hirano S, Mizutani C, Yamaguchi R, Miura O (1978) Formatoin of the polyelectrolyte
complexes of some acidic glycosaminoglycans with partially N-acylated chitosans. Biopolym
Orig Res Biomol 17(3):805–810
105. Chupa JM, Foster AM, Sumner SR, Madihally SV, Matthew HW (2000) Vascular cell
responses to polysaccharide materials: in vitro and in vivo evaluations. Biomater 21(22):2315–
2322
106. Mi FL, Tan YC, Liang HF, Sung HW (2002) In vivo biocompatibility and degradability of a
novel injectable-chitosan-based implant. Biomater 23(1):181–191
107. Martins AM, Eng G, Caridade SG, Mano JF, Reis RL, Vunjak-NovakovicG (2014) Electrically
conductive chitosan/carbon scaffolds for cardiac tissue engineering. Biomacromol 15(2):635–
643
108. Pok S, Benavides OM, Hallal P, Jacot JG (2014) Use of myocardial matrix in a chitosan-based
full-thickness heart patch. Tissue Eng Part A 20(13–14):1877–1887
109. Podichetty JT, Madihally SV (2014) Modeling of porous scaffold deformation induced by
medium perfusion. J Biomed Mater Res B: Appl Biomater 102(4):737–748
110. Sarasam AR, Krishnaswamy RK, Madihally SV (2006) Blending chitosan with polycaprolactone: effects on physicochemical and antibacterial properties. Biomacromol 7(4):1131–1138
111. Ratakonda S, Sridhar UM, Rhinehart RR, Madihally SV (2012) Assessing viscoelastic properties of chitosan scaffolds and validation with cyclical tests. Acta Biomater 8(4):1566–1575
112. Mombini S, Mohammadnejad J, Bakhshandeh B, Narmani A, Nourmohammadi J, Vahdat
S, Zirak S (2019) Chitosan-PVA-CNT nanofibers as electrically conductive scaffolds for
cardiovascular tissue engineering. Int J Biol Macromol 140:278–287
113. Xie D, Huang H, Blackwood K, MacNeil S (2010) A novel route for the production of chitosan/
poly (lactide-co-glycolide) graft copolymers for electrospinning. Biomed Mater 5(6):065016
114. Albanna MZ, Bou-Akl TH, Walters HL III, Matthew HW (2012) Improving the mechanical
properties of chitosan-based heart valve scaffolds using chitosan fibers. J Mech Behav Biomed
Mater 5(1):171–180
115. Savchenko A, Yin RT, Kireev D, Efim IR ov, Molokanova E (2021) Graphene-based scaffolds: fundamentals and applications for cardiovascular tissue engineering. Front. Bioeng.
Biotechnol 9:797340
116. Pok S, Vitale F, Eichmann SL, Benavides OM, Pasquali M, Jacot JG (2014) Biocompatible
carbon nanotube–chitosan scaffold matching the electrical conductivity of the heart. ACS
Nano 8(10):9822–9832
117. Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC (2014) Heart transplantation:
challenges facing the field. Cold Spring Harb Perspect Med 4(5):a015636
118. Lakshmanan R, Maulik N (2018) Development of next generation cardiovascular therapeutics
through bio-assisted nanotechnology. J Biomed Mater Res B: Appl Biomater 106(5):2072–
2083
119. Lakshmanan R, Krishnan UM, Sethuraman S (2012) Living cardiac patch: the elixir for cardiac
regeneration. Expert Opin Biol Ther 12(12):1623–1640
120. Kim HH, Kim SHL, Choi YH, Ahn YH, Hwang NS (2018) Biomaterials for stem cell
therapy for cardiac disease, in Biomimetic Medical Materials: from Nanotechnology to 3D
Bioprinting, vol 1064. Springer, Singapore, pp 181–193
440 A. M. Mahmoud et al.
121. Jayakumar R, Prabaharan M, Muzzarelli RA (eds) (2011) Chitosan for biomaterials I. Springer
122. Bakshi PS, Selvakumar D, Kadirvelu K, Kumar NS (2020) Chitosan as an environment
friendly biomaterial–a review on recent modifications and applications. Int J Biol Macromol
150:1072–1083
123. Prabaharan M, Rodriguez-Perez MA, De Saja JA, Mano JE (2007) Preparation and characterization of poly (L-lactic acid)-chitosan hybrid scaffolds with drug release capability. J Biomed
Mater Res Part B: Appl Biomaterials: Official J Soc Biomaterials Jpn Society Biomaterials
Australian Soc Biomater Korean Soc Biomaterials 81(2):427–434
124. Sivashankari PR, Prabaharan M (2016) Prospects of chitosan-based scaffolds for growth factor
release in tissue engineering. Int J Biol Macromol 93:1382–1389
125. Hussain A, Collins G, Yip D, Cho CH (2013) Functional 3-D cardiac co-culture model using
bioactive chitosan nanofiber scaffolds. Biotechnol Bioeng 110(2):637–647
126. Abedi A, Bakhshandeh B, Babaie A, Mohammadnejad J, Vahdat S, Mombeiny R, Moosavi
SR, Amini J, Tayebi L (2021) Concurrent application of conductive biopolymeric chitosan/
polyvinyl alcohol/MWCNTs nanofibers, intracellular signaling manipulating molecules and
electrical stimulation for more effective cardiac tissue engineering. Mater Chem Phys
258:123842
127. Kroustalli A, Zisimopoulou AE, Koch S, Rongen L, Deligianni D, Diamantouros S,
Athanassiou G, Kokozidou M, Mavrilas D, Jockenhoevel S (2013) Carbon nanotubes reinforced chitosan films: mechanical properties and cell response of a novel biomaterial for
cardiovascular tissue engineering. J Mater Sci Mater Med 24:2889–2896
128. Nigro P, Bassetti B, Cavallotti L, Catto V, Carbucicchio C, Pompilio G (2018) Cell therapy
for heart disease after 15 years: unmet expectations. Pharmacol Res 127:77–91
129. Sheng CC, Zhou L, Hao J (2013) Current stem cell delivery methods for myocardial repair.
BioMed Res Int
130. Edlinger C, Schreiber C, Wernly B, Anker A, Ruzicka K, Jung C, Hoope UC, Lichtenauer M
(2015) Stem cell therapy for myocardial infarction 2001–2013 revisited. Stem Cell Rev Rep
11:743–751
131. VenugopalJR, Prabhakaran MP,Mukherjee S, Ravichandran R, Dan K, Ramakrishna S (2012)
Biomaterial strategies for alleviation of myocardial infarction. J R Soc Interface 9(66):1–19
132. Zhou Y, Yamamoto Y, Xiao Z, Ochiya T (2019) The immunomodulatory functions of
mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med 8(7):1025
133. Ehler E, Jayasinghe SN (2014) Cell electrospinning cardiac patches for tissue engineering
the heart. Analyst 139(18):4449–4452
134. Liu Z, Wang H, Wang Y, Lin Q, Yao A, Cao F, Li D, Zhou J, Duan C, Du Z, Wang Y, Wang
C (2012) The influence of chitosan hydrogel on stem cell engraftment, survival and homing
in the ischemic myocardial microenvironment. Biomater 33(11):3093–3106
135. Zhang S, Zhang F, Feng B, Fan Q, Yang F, Shang D, Sui J, Zhao H (2015) Hematopoietic stem
cell capture and directional differentiation into vascular endothelial cells for metal stent-coated
chitosan/hyaluronic acid loading CD133 antibody. Tissue Eng Part A 21(5–6):1173–1183
136. Tsukamoto Y, Akagi T, Akashi M (2020) Vascularized cardiac tissue construction with
orientation by layer-by-layer method and 3D printer. Sci Rep 10(1):5484
137. Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, Dahlke MH (2010) The
immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy.
Int Immunopharmacol 10(12):1496–1500
138. Xu B, Li Y, Deng B, Liu X, Wang L, Zhu QL (2017) Chitosan hydrogel improves mesenchymal
stem cell transplant survival and cardiac function following myocardial infarction in rats. Exp
Ther Med 13(2):588–594
139. Wang H, Shi J, Wang Y, Yin Y,Wang L, Liu J, Liu Z, Duan C, Zhu P,Wang C (2014) Promotion
of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair
after myocardial infarction. Biomater 35(13):3986–3998
140. Hua C, Liu J, Hua X, Wang X (2020) Synergistic fabrication of dose-response chitosan/
dextran/β-glycerophosphate injectable hydrogel as cell delivery carrier for cardiac healing
after acute myocardial infarction. Dose-Response 18(3):1559325820941323
Chitosan/Carbon Nanocomposites in Drug Delivery and Cardiovascular … 441
141. Yu K, Wu S, Li H (2016) A chitosan-graft-PEI-eprosartan conjugate for cardiomyocytetargeted VEGF plasmid delivery in myocardial ischemia gene therapy. J Exp Nanosci
11(2):81–96
142. Jiang T, Xu L, Zhao M, Kong F, Lu X, Tang C, Yin C (2022) Dual targeted delivery of statins
and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy.
Biomater 280:121324
143. Nguyen MA, Wyatt H, Susser L, Geoffrion M, Rasheed A, Duchez AC, Cottee ML, Afolayan
E, Farah E, Kahiel Z, Côté M, Gadde S, Rayner KJ (2019) Delivery of microRNAs by chitosan
nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS
Nano 13(6):6491–6505
144. Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z (2019) Targeted thrombolysis by using c-RGDmodified N, N, N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind
Pharm 45(1):88–95
145. Fujita M, Ishihara M, Morimoto Y, Simizu M, Saito Y, Yura H, Matsui T, Takase B, Hattori H,
Kanatani Y, Kikuchi M, Maehara T (2005) Efficacy of photocrosslinkable chitosan hydrogel
containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J
Surg Res 126(1):27–33
146. Blan NR, Birla RK (2008) Design and fabrication of heart muscle using scaffold-based
tissue engineering. J Biomed Mater Res Part A: Official J Society Biomaterials Jpn Society
Biomaterials Australian Society Biomaterials Korean Society Biomaterials 86(1):195–208
147. Chi NH, Yang MC, Chung TW, Chou NK, Wang SS (2013) Cardiac repair using chitosanhyaluronan/silk fibroin patches in a rat heart model with myocardial infarction. Carbohydr
Polym 92(1):591–597
148. Kundu B, Rajkhowa R, Kundu SC, Wang X (2013) Silk fibroin biomaterials for tissue
regenerations. Adv Drug Deliv. Rev. 65(4):457–470
Graphene Reinforced Chitosan Nanocomposites for Drug Delivery
Ranganathan Priya, Seung Yun Nam, Wan-Seob Cho,
and Muthuchamy Maruthupandy
Abstract Chitosan (CTS) and graphene (GR) combinations are attracting the
interest of drug delivery sectors due to the combined effects of CTS, having exceptional biotic capabilities, and GR, which has excellent physical, chemical, rigid, and
spectral properties. CTS and GR composites can be used to create hydrogels, aerogels, scaffolds, films, and nanofibers. The efficiency of CTS/GR composite material
in different shapes may be increased even more by including various multifunctional
polymeric materials, nano-sized-particles, or proliferation factors due to the ease with
which these nanocomposites can be functionalized. Through this context in mind,
this chapter describes the most recent discoveries in CTS/GR composites in various
forms and compositions in drug delivery applications such as mouth, nostril, eye,
oral, lung, sublingual, skin, and anal drug delivery. Future directions for improvement
and obstacles for healthcare are also presented.
Keywords Chitosan
· Graphene · Nanocomposites · Spectral properties · Drug
delivery
R. Priya · S. Yun Nam (B)
Industry 4.0 Convergence Bionic Engineering, Pukyong National University, B usan 48513,
Republic of Korea
e-mail: mmarthupandy@yahoo.in
S. Yun Nam
Major of Biomedical Engineering, Division of Smart Healthcare, Pukyong National University,
Busan 48513, Republic of Korea
W.-S . Cho (
Lab of Toxicology, Department of Health Sciences, The Graduate School of Dong-A University,
37, Nakdong-daero 550 Beon-gil, Saha-gu, Busan 49315, Republic of Korea
e-mail: wcho@dau.ac.kr
M. Maruthupandy
e-mail: synam@pknu.ac.kr
) · M. Maruthupandy (B)
B
443
444 R. Priya et al.
Abbreviations
CPT Camptothecin
CS-DA-LAG Dihydrocaffeic acid and L-arginine-cografted chitosan
CTS Chitosan
DOX Doxorubicin
FA Folic acid
GM Glycidyl methacrylate
GO Graphene oxide
GR Graphene
PEG Polyethylene glycol
PEGS-PBA-BA Polyethylene glycol-co-poly (glycerol sebacic acid) difunction-
alized with phenylboronic acid and benzaldehyde
PHAs Polyhydroxyalkanoates
PLA Polylactic acid
PVP Polyvinylpyrrolidone
QCSG Glycidyl methacrylate functionalized quaternized chitosan
rGO Reduced graphene oxide
rGO@PDA Polydopamine-coated rGO
1 Introduction
The invention of determined, maintained, controlled drug delivery mechanisms with
minimum systemic adverse effects becomes an important subject throughout the
healthcare or legitimate industry t o attaining great pharmaceutical agent efficacy for
tumor treatment for the recent years [1, 2]. Current therapeutic and diagnostic technologies are highly effective in this context, yet their use have several adverse effects,
including chemotherapy drug that have no area targeted and are eliminated through
the human system with no generating the desired impact due to their decreased
molecular weight (Fig. 1)[3–5]. Therefore, in order to overcome these obstacles
and enhance drug water s olubility, regulated release-drug delivery mechanisms were
invented or built for the therapeutic medicine delivery at a particular biological site of
the human body [6, 7]. These systems ought to be mechanically stable, biocompatible, inert, without leachable contaminants, easy to deliver to patients, and easy
to remove [8]. Organic and manmade polymers with biodegradable characteristics have been frequently employed in medication delivery. The majority of the
aforementioned requirements for the formation or construction of an effective drug
delivery systems are met by them. Examples of commonly used polymers for drug
delivery systems include polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP),
polylactic acid (PLA), polyhydroxyalkanoates (PHAs), poly (L-glutamic acid), guar
gum, chitin, chitosan, cellulose, gelatin, and others [9]. Chitosan, an organic polymer,
is recognized to be one among the most promising solutions for clinical use due to